Overview

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, efficacy, and dose response of brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of allergen-induced conjunctival redness using a conjunctival allergen challenge (CAC) model. It is hypothesized that low-dose brimonidine tartrate ophthalmic solution will be more effective than vehicle in the prevention of conjunctival redness induced by conjunctival allergen challenge when instilled prior to the allergen challenge.

Phase:

Phase 2

Details

Lead Sponsor:

Eye Therapies, LLC

Collaborator:

ORA, Inc.

Treatments:

Brimonidine Tartrate
Ophthalmic Solutions
Oxymetazoline
Phenylephrine